Hsu: The optimal biotech model is between fully virtual and vertically integrated
Patrick Hsu · No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute · Feb 25, 2025 · at 47:25
Patrick Hsu, CEO and co-founder of the Arc Institute, analyzes biotech business model evolution on No Priors.
0:00 / 0:21exact quote · 21.5s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Previously the virtual biotech was a concept that was very much in fashion, right? Folks found out just In reality, when you try to do this, even though it looks really good on paper, it's incredibly slow, right? So then folks tried the other way, which is let's just fully vertically integrate and just own everything. Well, that was incredibly expensive, right? And obviously the answer is maybe more Goldilocks in the middle.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Patrick Hsu
Hsu: High-throughput token generation will dominate biology over mechanistic research
“The vast majority of, you know, mechanistic data that's been generated to date is really made to ask very specific, very well scoped questions and just, you know, way more tokens per experiment is, you know, just, it's just going to be the way to do it.”
Hsu: Scientific research and creativity fundamentally involve hallucination
“People criticize these models for hallucinating, but if you think about it, the process of scientific research just involves hallucination, right? That's what creativity is.”
Hsu: Biological scaling laws hold across proteins, DNA, and inference compute
“We've, we're seeing evidence of scaling laws in biology across proteins, right? That's been shown in the protein language models across DNA, which is what we've shown in our EVO series of models from ARC. We're also seeing inference time scaling laws which in,…”